Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14423078 | 0.77 | — | — | |
| SCHEMBL9834992 | 0.75 | F2 (0.38) | F2ELANECTSGCTRC | |
| SCHEMBL19546254 | 0.75 | F2 (0.38) | F2ELANECTSGCTRC | |
| SCHEMBL10548865 | 0.74 | CYP3A4 (0.38) | — | |
| SCHEMBL10963708 | 0.74 | F2 (0.37) | F2ELANECTSGCTRC | |
| SCHEMBL24658350 | 0.73 | F2 (0.35) | F2ELANECTSGCTRC | |
| SCHEMBL16613893 | 0.73 | F2 (0.35) | F2ELANECTSGCTRC | |
| SCHEMBL584680 | 0.72 | LMNA (0.35) | — | |
| SCHEMBL10965861 | 0.71 | HDAC6 (0.35) | F2ELANECTSGCTRC | |
| SCHEMBL19923761 | 0.70 | F2 (0.32) | F2ELANECTSGCTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1037868-A2 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999026909-A2 | ALPHA-HYDROXY, -AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | MMP1, MMP8, HRH3 | F2 757/4885ELANE 208/4885CTSG 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.